<SEC-DOCUMENT>0001104659-25-072516.txt : 20250731
<SEC-HEADER>0001104659-25-072516.hdr.sgml : 20250731
<ACCEPTANCE-DATETIME>20250731090622
ACCESSION NUMBER:		0001104659-25-072516
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250731
DATE AS OF CHANGE:		20250731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		251169689

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2522111d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(Amendment
No.&#8239;&#8239;&#8239;&#8239;&#8239;) </B></FONT>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed by
the Registrant <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of registrant as specified in its charter)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of person(s) filing proxy statement, if
other than the registrant) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2522111d1_defa14aimg001.jpg" ALT="" STYLE="height: 88px; width: 345px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPLEMENT TO DEFINITIVE PROXY STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON
AUGUST 5, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This supplement
(the &ldquo;Supplement&rdquo;), dated July 31, 2025, supplements the definitive proxy statement on Schedule 14A (the &ldquo;Proxy Statement&rdquo;)
filed by Carisma Therapeutics Inc., a Delaware corporation (&ldquo;Carisma&rdquo;), with the U.S. Securities and Exchange Commission
(the &ldquo;SEC&rdquo;), on July 7, 2025 and provided to Carisma&rsquo;s stockholders in connection with the solicitation of proxies
by the Carisma&rsquo;s Board of Directors for use at the Special Meeting of Stockholders (the &ldquo;Special Meeting&rdquo;) to be held
on August 5, 2025 at 10:00 a.m. Eastern Time via the Internet at&nbsp;</FONT><I><U>https://meetnow.global/MDJSZWU</U>. </I>Except where
the context otherwise requires, references to &ldquo;Carisma,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; and similar
terms refer to Carisma Therapeutics Inc. and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>YOUR VOTE IS IMPORTANT TO US. WHETHER OR NOT YOU PLAN TO ATTEND
THE SPECIAL MEETING ONLINE, WE URGE YOU TO VOTE YOUR SHARES BY SUBMITTING YOUR PROXY OVER THE INTERNET OR BY TELEPHONE, OR BY COMPLETING,
DATING, SIGNING AND RETURNING THE PROXY CARD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are holding the Special Meeting to allow our stockholders to authorize
our Board of Directors to effect a reverse stock split of our common stock. The proposed reverse stock split is expected to be needed
for us to comply with applicable listing criteria for our common stock to continue to trade on the Nasdaq Capital Market and, accordingly,
to avoid a delisting of our common stock from Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders
are also reminded that, on June 23, 2025, we filed with the SEC a Current Report on Form 8-K disclosing that, on June 22, 2025, we entered
into an Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;) with Azalea Merger Sub, Inc., a Delaware corporation and our
wholly owned subsidiary (&ldquo;Merger Sub&rdquo;), Ocugen, Inc. (&ldquo;Ocugen&rdquo;), a Delaware corporation, and OrthoCellix, Inc.,
a Delaware corporation and wholly-owned subsidiary of Ocugen (&ldquo;OrthoCellix&rdquo;), pursuant to which, among other matters, and
subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into OrthoCellix
(the &ldquo;Merger&rdquo;), with OrthoCellix continuing as our wholly owned subsidiary and the surviving company of the Merger. On July
21, 2025, in connection with the proposed Merger, Carisma filed with the SEC a </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000141057825001470/tmb-20250331xs4.htm">Registration Statement on Form S-4</A> which contains
a proxy statement and prospectus that includes further information about OrthoCellix and the proposed Merger. As discussed in the Proxy
Statement, although the proposed reverse stock split is likely necessary to increase our common stock price to meet the minimum closing
price requirement for filing an initial listing application with Nasdaq in connection with the closing of the contemplated Merger, we
will need to hold a separate special meeting of our stockholders in order to obtain the stockholder approvals necessary to complete the
Merger and related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>YOUR PARTICIPATION IS IMPORTANT. PLEASE VOTE YOUR SHARES AS SOON
AS POSSIBLE TO ALLOW US TO COMPLETE THE PROPOSED REVERSE STOCK SPLIT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Supplement&nbsp;should be read in conjunction with the Proxy Statement,
which we urge you to read in its entirety. This Supplement does not change the proposals to be acted on at the Special Meeting or the
recommendations our Board of Directors with respect to the proposals, which are described in the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2522111d1_defa14aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2522111d1_defa14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !8 5D# 2(  A$! Q$!_\0
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M -(T-==H]"O7C8JRPL0P."#BJ%KH$4UA!-]MOTE>-6W"Y;@D9Z'BKVO_ /(
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1*** #%%%% !@>E&*** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
